NANOCHON: Funding, Investors & Team (Oct 2026)
At present, there is an established clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, today’s standard replacement joints are very invasive, and not permanent. The lifespan of common replacement joints limits their effective use in patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options. Nanochon, is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
NANOCHON has raised $9.9M across 5 funding rounds on record, the most recent a Seed of $4.1M announced in Jan 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NANOCHON Company Profile and Key Stats
Latest funding round on record: Jan 2026.
NANOCHON Funding Rounds
2 of 5 rounds were announced without a disclosed amount and are excluded from the total.
NANOCHON raised $1.8M in an undisclosed round announced in Aug 2023.
3 months later, an undisclosed round was announced in Nov 2023 with no disclosed amount.
6 months later, a Seed of $4.0M was announced in May 2024.
1.4 years later, an undisclosed round was announced in Oct 2025 with no disclosed amount.
3 months later, a Seed of $4.1M was announced in Jan 2026.
NANOCHON Founders and Leadership Team
No contact details are on record for this team yet.
NANOCHON Funding Compared to Other Biotechnology Startups
NANOCHON's latest round of $4.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NANOCHON in Biotechnology and Virginia
Companies Similar to NANOCHON
BioLinker is a creation of manufactured science, protein blend packs, and protein.
WhiteLab Genomics develops digital tools that help gene and cell therapy companies develop cheaper drugs…
Tydra Labs is a biotechnology company that transforms crustacean shell waste into chitin and bio-products.
M-Based develops new alternative material technologies using mushrooms. 🍄 We consider environmental…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
NANOCHON Funding FAQs
What does NANOCHON do?
At present, there is an established clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, today’s standard replacement joints are very invasive, and not permanent. The lifespan of common replacement joints limits their effective use in patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options. Nanochon, is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
How much funding has NANOCHON raised?
NANOCHON has raised $9.9M across 5 rounds on record. The most recent is a Seed of $4.1M announced in Jan 2026.
When did NANOCHON last raise funding?
NANOCHON's most recent funding round on record is a Seed of $4.1M, announced in Jan 2026.
Who is the CEO of NANOCHON?
Benjamin Holmes is listed as CEO at NANOCHON.
Where is NANOCHON headquartered?
NANOCHON is based in Virginia, Usulutan, El Salvador.
How many employees does NANOCHON have?
NANOCHON is in the 1-10 employee band.
How does NANOCHON's funding compare to other Biotechnology startups?
NANOCHON's latest round of $4.1M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NANOCHON Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NANOCHON is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.